Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching

Therapeutic Drug Monitoring

Volumn 29, Issue 6, 2007, Pages 767-772

  Waldschmitt, Christine ^a   Vogel, Friederike ^a   Maurer, Christian ^a   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Column switching; Duloxetine; High performance liquid chromatography; Interactions; Therapeutic drug monitoring

Indexed keywords

ACETONITRILE; AMISULPRIDE; AMITRIPTYLINE; ARIPIPRAZOLE; CHLORPROTHIXENE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 INHIBITOR; DEHYDROARIPIPRAZOLE; DIAZEPAM; DONEPEZIL; DOXEPIN; DRUG METABOLITE; DULOXETINE; FLUOXETINE; IMIPRAMINE; LITHIUM; LORAZEPAM; METOPROLOL; MIRTAZAPINE; NORCITALOPRAM; NORCLOMIPRAMINE; NORCLOZAPINE; OLANZAPINE; POTASSIUM DIHYDROGEN PHOSPHATE; PROPRANOLOL; SILICON DIOXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; BLOOD; CENTRIFUGATION; CONTROLLED STUDY; DEPRESSION; DRUG DETERMINATION; DRUG MONITORING; DRUG RETENTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PLASMA; PRIORITY JOURNAL; SPECTROPHOTOMETRY; STATISTICAL SIGNIFICANCE; ULTRAVIOLET SPECTROSCOPY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; MOLECULAR STRUCTURE; SEROTONIN UPTAKE INHIBITORS; SPECTROPHOTOMETRY; THIOPHENES;

EID: 36549022715     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815d0dfa     Document Type: Article

References (21)

1. Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med. 2005;3:449-456.
2. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry. 2002;52:1166-1174.
3. Hunziker ME, Suehs BT, Bettinger TL, et al. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005;27:1126-1143.
4. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. Psychiatr Res J. 2002;36:383-390.
5. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63:308-315.
6. Fava M, Detke MJ, Balestrieri M, et al. Management of depression relapse: re-initiation of duloxetine treatment or dose increase. J Psychiatr Res. 2006;40:328-336.
7. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-365.
8. Härtter S, Hiemke C. Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. J Chromatogr. 1992;578:273-282.
9. Veuthey JL, Souverain S, Rudaz S. Column-switching procedures for the fast analysis of drugs in biologic samples. Ther Drug Monit. 2004;26:161-166.
10. Causon R. Validation of chromatographic methods in biomedical analysis: viewpoint and discussion. J Chromatogr B Biomed Sci Appl. 1997;689:175-180.
11. Anderson D, Reed S, Lintemoot J, et al. A first look at duloxetine (Cymbalta) in a postmortem laboratory. J Anal Toxicol. 2006;30:576-580.
12. Ma N, Zhang BK, Li HD, et al. Determination of duloxetine in human plasma via LC/MS and subsequent application to a pharmacokinetic study in healthy Chinese volunteers. Clin Chim Acta. 2007;380:100-105. E-pub 2007 Jan 26.
13. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31:1142-1150.
14. Chan C, Yeo KP, Pan AX, et al. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. Br J Clin Pharmacol. 2007;63:310-314.
15. Lindell M, Karlsson MO, Lennernas H, et al. Variable expression of CYP and Pgp genes in human small intestine. Eur J Clin Invest. 2003;33:493-499.
16. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73:170-177.
17. Turcotte JE, Debonnel G, de Montigny C, et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24:511-521.
18. Takano A, Suzuki K, Kosaka J, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology. 2006;185:395-399.
19. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826-835.
20. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 1999;60:36-40.
21. Rasmussen BB, Brix TH, Kyvik KO, et al. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics. 2002;12:473-478.